Trek Therapeutics Continues to Develop HCV Drugs
Infectious disease expert Robert Hindes, MD, serves as the chief medical officer of Trek Therapeutics, a company he cofounded. Robert Hindes, MD, focuses his efforts on developing affordable and accessible treatments for chronic hepatitis C (HCV) and other viral infections.

Trek Therapeutics was created in 2014 by a team of experienced researchers and medical professionals. The company’s founders previously helped to develop seven FDA-approved antiviral drugs among themselves, and sought to continue developing cures with likeminded individuals. Trek is a Public Benefit Corporation, and has a mission to serve the needs of patients worldwide by increasing access and availability of drugs.

Trek’s first development efforts will focus on developing highly effective and affordable drugs for HCV. The company is well on its way to this goal, and is currently investigating the safety and efficacy of two drugs: Faldaprevir and TD-6450.

After Trek develops satisfactory cures for HCV, the company intends to turn its attention to other infectious diseases. The company would like to focus on serious diseases where the medical breakthroughs would be most useful.
Trek Therapeutics Continues to Develop HCV Drugs
0
13
0
Published:

Trek Therapeutics Continues to Develop HCV Drugs

Infectious disease expert Robert Hindes, MD, serves as the chief medical officer of Trek Therapeutics, a company he cofounded. Robert Hindes, MD, Read More
0
13
0
Published:

Creative Fields